Asset Management Corp’s CRISPR Therapeutics CRSP Stock Holding History

Asset Management Corp’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$343K	Sell	7,580 -2,875	-27%	-$140K	0.27%	80
2022 Q4	$425K	Sell	10,455 -1,175	-10%	-$62.3K	0.36%	78
2022 Q3	$760K	Hold	11,630	–	–	0.46%	45
2022 Q2	$707K	Sell	11,630 -800	-6%	-$47K	0.46%	50
2022 Q1	$780K	Buy	12,430 +1,365	+12%	+$85.7K	0.39%	62
2021 Q4	$839K	Buy	11,065 +288	+3%	+$25.2K	0.42%	61
2021 Q3	$1.21M	Buy	10,777 +1,127	+12%	+$142K	0.6%	42
2021 Q2	$1.56M	Sell	9,650 -1,270	-12%	-$154K	0.9%	28
2021 Q1	$1.33K	Buy	10,920 +7,970	+270%	+$1.2M	0.57%	38
2020 Q4	$590K	Hold	2,950	–	–	0.33%	78
2020 Q3	$247K	Buy	+2,950	New	+$262K	0.15%	123

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Asset Management Corp's CRSP Position: Q1 2023 in Review

Asset Management Corp reduced its CRISPR Therapeutics (CRSP) stake by 27% in Q1 2023, selling an estimated $140K and leaving 7,580 shares worth $343K. The position accounts for 0.27% of the portfolio, ranked #80.

Asset Management Corp first reported a position in CRSP in Q3 2020 and has held it in 11 quarters since. The position peaked at $1.56M in Q2 2021. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

Asset Management Corp held 7,580 shares of CRISPR Therapeutics worth $343K as of Q1 2023.
Asset Management Corp sold 2,875 CRISPR Therapeutics shares in Q1 2023, an estimated $140K.
CRISPR Therapeutics made up 0.27% of Asset Management Corp's portfolio in Q1 2023, its #80 holding.
Asset Management Corp first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 11 quarters since.
Asset Management Corp's CRISPR Therapeutics position peaked at $1.56M in Q2 2021.
381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Asset Management Corp's 13F filing for Q1 2023, filed 14 Apr 2023.